ERIS Lifesciences has acquired Swiss Parenterals Ltd for an undisclosed amount, marking a significant expansion in its pharmaceutical operations. Swiss Parenterals, established in 1987 as a manufacturer and exporter of pharmaceutical formulations, has grown into a global pharmaceutical CRAMS (Contract Research and Manufacturing Services) organization. It is recognized for providing affordable, high-quality medicines, with a focus on Pharmaceuticals, Nutraceuticals, and Medicated Cosmeceuticals, and an extensive global reach.
This acquisition is strategic for ERIS Lifesciences, a healthcare firm, aiming to bolster its manufacturing capabilities and international presence. Swiss Parenterals brings strong credentials, including EU-GMP, Australian TGA, Brazilian ANVISA, Mexican Cofepris, and PIC/s approvals for its sterile injectable facilities. Its expertise spans generic and specialty sterile injectables, product development, manufacturing, and dossier creation, with over 1,000 approved dossiers for approximately 190 unique molecules. The company exports its products to more than 80 countries worldwide.
The integration is expected to yield substantial synergies for ERIS. It provides immediate access to state-of-the-art manufacturing plants in Ahmedabad, India, equipped with sterile and oral dosage handling capabilities, significantly expanding ERIS’s production capacity. Furthermore, Swiss Parenterals' globally accredited facilities and broad product range, including parenterals, oral solids, semi-solids, and nutritional supplements, will diversify ERIS’s existing portfolio and accelerate its entry into new international markets facilitated by an established export network and regulatory support.
This strategic purchase by ERIS Lifesciences aims to leverage Swiss Parenterals’ robust manufacturing infrastructure and global export network. The combined entity is positioned to strengthen its competitive standing in the pharmaceutical industry, enhancing its ability to serve a wider range of global markets with a more comprehensive and specialized product offering. The move reflects ERIS's commitment to growth through strategic expansion of its capabilities and market footprint.